Literature analysis of rhabdomyolysis induced by bezafibrate
10.12206/j.issn.2097-2024.202404081
- VernacularTitle:苯扎贝特致横纹肌溶解病例文献分析
- Author:
Qiuya YANG
1
;
Xia LIU
1
Author Information
1. Department of Pharmacy, Shanghai Taikang Shenyuan Rehabilitation Hospital, Shanghai 201620, China.
- Publication Type:Pharmacyadministration
- Keywords:
bezafibrate;
rhabdomyolysis;
literature;
analysis
- From:
Journal of Pharmaceutical Practice and Service
2025;43(8):414-420
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the causes of adverse reactions induced by bezafibrate, study the clinical characteristics of rhabdomyolysis, and provide reference for clinical rational use. Methods The case reports of bezafibrate induced rhabdomyolysis were collected from domestic and foreign databases （from January 1, 2000 to November 30, 2023）, and the relevant basic data were extracted for statistical analysis. The rationality and adverse reaction relevance of bezafibrate use which met the inclusion criteria were evaluated. Results A total of 26 cases of bezafibrate induced rhabdomyolysis were reported, including 28 patients. There were 10 males and 18 females, with an average age of （64.57±11.20） years， the occurrence time of adverse reaction was 6 d（4 d, 8.5 d）. All patients had other diseases except hyperlipemia. The creatinine clearance rate （CCR） of patients was generally less than 80ml/min. There were 16 patients were given over-dosed bezafibrate. Conclusion The drug instruction of bezafibrate should be regulated and managed by National Regulatory Authority. In clinical application, attention should be paid to the rationality of medication use, ADR monitoring and patient education.
